SIMILAR PATTERN OF AMINO ACIDS MAPPED TO '7YS'

List of Similar Pattern of Amino Acids

Hit pattern: 3D amino acid arrangements similar to known drug binding site
Query pattern: Residues from known binding site for annotated drug that match the hit pattern

(Click on the DrReposER ID to view details on interfaces and similar patterns of amino acids)
(Click on the view link on the last column to view superposed patterns of amino acids)

Filter list by:

	DrReposER ID / Desc.	Hit PDBID	Hit Macromolecule	Res. Matches	Interface	HETATM	RMSD	Dali Z-score	Seq. Identity (%)
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1IEP_B_STIB202_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL)	5u6b	TYROSINE-PROTEIN KINASE RECEPTOR UFO (Homo sapiens)	6 / 12	LEU A 542 VAL A 550 ALA A 565 PHE A 622 GLY A 626 ALA A 689	7YS A9001 (-4.1A) 7YS A9001 (-4.2A) 7YS A9001 (-3.3A) 7YS A9001 (-4.3A) 7YS A9001 (-3.4A) 7YS A9001 (-3.4A)	0.75A	1iepB-5u6bA: 29.7	1iepB-5u6bA: 43.40
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2G72_B_SAMB2002_1 (PHENYLETHANOLAMINE N-METHYLTRANSFERASE)	5u6b	TYROSINE-PROTEIN KINASE RECEPTOR UFO (Homo sapiens)	4 / 7	GLY A 692 TYR A 726 ASP A 690 ASP A 627	None None None 7YS A9001 (-3.5A)	0.90A	2g72B-5u6bA: undetectable	2g72B-5u6bA: 19.35
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2WGJ_A_VGHA2346_1 (HEPATOCYTE GROWTH FACTOR RECEPTOR)	5u6b	TYROSINE-PROTEIN KINASE RECEPTOR UFO (Homo sapiens)	7 / 12	GLY A 543 VAL A 550 ALA A 565 LEU A 620 MET A 623 GLY A 626 MET A 679	7YS A9001 ( 4.2A) 7YS A9001 (-4.2A) 7YS A9001 (-3.3A) 7YS A9001 (-4.2A) 7YS A9001 (-4.7A) 7YS A9001 (-3.4A) 7YS A9001 (-3.5A)	0.73A	2wgjA-5u6bA: 32.6	2wgjA-5u6bA: 41.61
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2WGJ_A_VGHA2346_1 (HEPATOCYTE GROWTH FACTOR RECEPTOR)	5u6b	TYROSINE-PROTEIN KINASE RECEPTOR UFO (Homo sapiens)	8 / 12	VAL A 550 ALA A 565 LEU A 620 MET A 623 GLY A 626 MET A 679 ALA A 689 ASP A 690	7YS A9001 (-4.2A) 7YS A9001 (-3.3A) 7YS A9001 (-4.2A) 7YS A9001 (-4.7A) 7YS A9001 (-3.4A) 7YS A9001 (-3.5A) 7YS A9001 (-3.4A) None	0.64A	2wgjA-5u6bA: 32.6	2wgjA-5u6bA: 41.61
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2XP2_A_VGHA9000_1 (TYROSINE-PROTEIN KINASE RECEPTOR)	5u6b	TYROSINE-PROTEIN KINASE RECEPTOR UFO (Homo sapiens)	7 / 9	LEU A 542 VAL A 550 ALA A 565 LEU A 620 MET A 623 GLY A 626 ASP A 690	7YS A9001 (-4.1A) 7YS A9001 (-4.2A) 7YS A9001 (-3.3A) 7YS A9001 (-4.2A) 7YS A9001 (-4.7A) 7YS A9001 (-3.4A) None	0.51A	2xp2A-5u6bA: 30.5	2xp2A-5u6bA: 40.67
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3AOX_A_EMHA901_1 (ALK TYROSINE KINASE RECEPTOR)	5u6b	TYROSINE-PROTEIN KINASE RECEPTOR UFO (Homo sapiens)	6 / 10	LEU A 542 ALA A 565 LYS A 567 LEU A 620 MET A 623 GLY A 626	7YS A9001 (-4.1A) 7YS A9001 (-3.3A) None 7YS A9001 (-4.2A) 7YS A9001 (-4.7A) 7YS A9001 (-3.4A)	0.68A	3aoxA-5u6bA: 29.5	3aoxA-5u6bA: 38.46
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3CS9_A_NILA600_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	5u6b	TYROSINE-PROTEIN KINASE RECEPTOR UFO (Homo sapiens)	5 / 10	LEU A 542 VAL A 550 LYS A 567 PHE A 622 VAL A 688	7YS A9001 (-4.1A) 7YS A9001 (-4.2A) None 7YS A9001 (-4.3A) None	0.89A	3cs9A-5u6bA: 30.4	3cs9A-5u6bA: 43.27
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3CS9_A_NILA600_2 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	5u6b	TYROSINE-PROTEIN KINASE RECEPTOR UFO (Homo sapiens)	5 / 12	ALA A 565 GLY A 626 PHE A 668 HIS A 670 ALA A 689	7YS A9001 (-3.3A) 7YS A9001 (-3.4A) None None 7YS A9001 (-3.4A)	0.32A	3cs9A-5u6bA: 30.4	3cs9A-5u6bA: 43.27
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3CS9_C_NILC600_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	5u6b	TYROSINE-PROTEIN KINASE RECEPTOR UFO (Homo sapiens)	5 / 12	ALA A 565 PHE A 622 PHE A 668 HIS A 670 ALA A 689	7YS A9001 (-3.3A) 7YS A9001 (-4.3A) None None 7YS A9001 (-3.4A)	0.53A	3cs9C-5u6bA: 26.9	3cs9C-5u6bA: 43.27
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3CS9_D_NILD600_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	5u6b	TYROSINE-PROTEIN KINASE RECEPTOR UFO (Homo sapiens)	6 / 12	ALA A 565 PHE A 622 GLY A 626 PHE A 668 HIS A 670 ALA A 689	7YS A9001 (-3.3A) 7YS A9001 (-4.3A) 7YS A9001 (-3.4A) None None 7YS A9001 (-3.4A)	0.49A	3cs9D-5u6bA: 29.3	3cs9D-5u6bA: 43.27
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3MIY_A_B49A1_1 (TYROSINE-PROTEIN KINASE ITK/TSK)	5u6b	TYROSINE-PROTEIN KINASE RECEPTOR UFO (Homo sapiens)	6 / 11	ALA A 565 LYS A 567 PHE A 622 MET A 623 GLY A 626 ASP A 690	7YS A9001 (-3.3A) None 7YS A9001 (-4.3A) 7YS A9001 (-4.7A) 7YS A9001 (-3.4A) None	0.81A	3miyA-5u6bA: 32.2	3miyA-5u6bA: 36.93
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3MIY_B_B49B2_1 (TYROSINE-PROTEIN KINASE ITK/TSK)	5u6b	TYROSINE-PROTEIN KINASE RECEPTOR UFO (Homo sapiens)	5 / 9	ALA A 565 LYS A 567 PHE A 622 MET A 623 GLY A 626	7YS A9001 (-3.3A) None 7YS A9001 (-4.3A) 7YS A9001 (-4.7A) 7YS A9001 (-3.4A)	0.63A	3miyB-5u6bA: 31.7	3miyB-5u6bA: 36.93
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3VAQ_A_ADNA401_2 (PUTATIVE ADENOSINE KINASE)	5u6b	TYROSINE-PROTEIN KINASE RECEPTOR UFO (Homo sapiens)	4 / 4	LEU A 620 ALA A 689 PHE A 691 ASN A 681	7YS A9001 (-4.2A) 7YS A9001 (-3.4A) None None	1.43A	3vaqA-5u6bA: undetectable	3vaqA-5u6bA: 22.60
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3ZBF_A_VGHA3000_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS)	5u6b	TYROSINE-PROTEIN KINASE RECEPTOR UFO (Homo sapiens)	7 / 12	LEU A 542 ALA A 565 LEU A 620 MET A 623 GLY A 626 ASP A 627 ASP A 690	7YS A9001 (-4.1A) 7YS A9001 (-3.3A) 7YS A9001 (-4.2A) 7YS A9001 (-4.7A) 7YS A9001 (-3.4A) 7YS A9001 (-3.5A) None	0.63A	3zbfA-5u6bA: 26.3	3zbfA-5u6bA: 38.07
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4ANQ_A_VGHA9000_1 (ALK TYROSINE KINASE RECEPTOR)	5u6b	TYROSINE-PROTEIN KINASE RECEPTOR UFO (Homo sapiens)	8 / 9	LEU A 542 VAL A 550 ALA A 565 LEU A 620 MET A 623 GLY A 626 ALA A 689 ASP A 690	7YS A9001 (-4.1A) 7YS A9001 (-4.2A) 7YS A9001 (-3.3A) 7YS A9001 (-4.2A) 7YS A9001 (-4.7A) 7YS A9001 (-3.4A) 7YS A9001 (-3.4A) None	0.60A	4anqA-5u6bA: 30.3	4anqA-5u6bA: 40.30
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4ANS_A_VGHA9000_1 (ALK TYROSINE KINASE RECEPTOR)	5u6b	TYROSINE-PROTEIN KINASE RECEPTOR UFO (Homo sapiens)	7 / 9	LEU A 542 VAL A 550 ALA A 565 MET A 623 GLY A 626 ALA A 689 ASP A 690	7YS A9001 (-4.1A) 7YS A9001 (-4.2A) 7YS A9001 (-3.3A) 7YS A9001 (-4.7A) 7YS A9001 (-3.4A) 7YS A9001 (-3.4A) None	0.61A	4ansA-5u6bA: 30.2	4ansA-5u6bA: 40.48
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4MXY_B_DB8B601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	5u6b	TYROSINE-PROTEIN KINASE RECEPTOR UFO (Homo sapiens)	7 / 12	LEU A 542 VAL A 550 ALA A 565 LYS A 567 GLY A 626 ALA A 689 ASP A 690	7YS A9001 (-4.1A) 7YS A9001 (-4.2A) 7YS A9001 (-3.3A) None 7YS A9001 (-3.4A) 7YS A9001 (-3.4A) None	0.65A	4mxyB-5u6bA: 30.3	4mxyB-5u6bA: 37.38
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4MXZ_B_DB8B601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	5u6b	TYROSINE-PROTEIN KINASE RECEPTOR UFO (Homo sapiens)	7 / 12	LEU A 542 VAL A 550 ALA A 565 LYS A 567 GLY A 626 ALA A 689 ASP A 690	7YS A9001 (-4.1A) 7YS A9001 (-4.2A) 7YS A9001 (-3.3A) None 7YS A9001 (-3.4A) 7YS A9001 (-3.4A) None	0.65A	4mxzB-5u6bA: 30.3	4mxzB-5u6bA: 37.38
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4OTI_A_MI1A1001_1 (SERINE/THREONINE-PRO TEIN KINASE N1)	5u6b	TYROSINE-PROTEIN KINASE RECEPTOR UFO (Homo sapiens)	7 / 12	LEU A 542 GLY A 543 GLY A 545 GLY A 548 VAL A 550 ALA A 565 LYS A 567	7YS A9001 (-4.1A) 7YS A9001 ( 4.2A) None None 7YS A9001 (-4.2A) 7YS A9001 (-3.3A) None	0.63A	4otiA-5u6bA: 20.0	4otiA-5u6bA: 27.96
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4TWP_A_AXIA601_1 (TYROSINE-PROTEIN KINASE ABL1)	5u6b	TYROSINE-PROTEIN KINASE RECEPTOR UFO (Homo sapiens)	9 / 12	LEU A 542 VAL A 550 ALA A 565 LYS A 567 PHE A 622 MET A 623 GLY A 626 ASN A 677 ASP A 690	7YS A9001 (-4.1A) 7YS A9001 (-4.2A) 7YS A9001 (-3.3A) None 7YS A9001 (-4.3A) 7YS A9001 (-4.7A) 7YS A9001 (-3.4A) None None	0.75A	4twpA-5u6bA: 30.4	4twpA-5u6bA: 42.68
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4TWP_A_AXIA601_1 (TYROSINE-PROTEIN KINASE ABL1)	5u6b	TYROSINE-PROTEIN KINASE RECEPTOR UFO (Homo sapiens)	9 / 12	VAL A 550 ALA A 565 LYS A 567 PHE A 622 MET A 623 GLY A 626 ASN A 677 ALA A 689 ASP A 690	7YS A9001 (-4.2A) 7YS A9001 (-3.3A) None 7YS A9001 (-4.3A) 7YS A9001 (-4.7A) 7YS A9001 (-3.4A) None 7YS A9001 (-3.4A) None	0.72A	4twpA-5u6bA: 30.4	4twpA-5u6bA: 42.68
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4TWP_B_AXIB601_1 (TYROSINE-PROTEIN KINASE ABL1)	5u6b	TYROSINE-PROTEIN KINASE RECEPTOR UFO (Homo sapiens)	9 / 12	LEU A 542 VAL A 550 ALA A 565 LYS A 567 PHE A 622 MET A 623 GLY A 626 ALA A 689 ASP A 690	7YS A9001 (-4.1A) 7YS A9001 (-4.2A) 7YS A9001 (-3.3A) None 7YS A9001 (-4.3A) 7YS A9001 (-4.7A) 7YS A9001 (-3.4A) 7YS A9001 (-3.4A) None	0.79A	4twpB-5u6bA: 30.2	4twpB-5u6bA: 42.68
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4TWP_B_AXIB601_1 (TYROSINE-PROTEIN KINASE ABL1)	5u6b	TYROSINE-PROTEIN KINASE RECEPTOR UFO (Homo sapiens)	9 / 12	LEU A 542 VAL A 550 ALA A 565 PHE A 622 MET A 623 GLY A 626 ASN A 677 ALA A 689 ASP A 690	7YS A9001 (-4.1A) 7YS A9001 (-4.2A) 7YS A9001 (-3.3A) 7YS A9001 (-4.3A) 7YS A9001 (-4.7A) 7YS A9001 (-3.4A) None 7YS A9001 (-3.4A) None	0.76A	4twpB-5u6bA: 30.2	4twpB-5u6bA: 42.68
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4U5J_A_RXTA601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	5u6b	TYROSINE-PROTEIN KINASE RECEPTOR UFO (Homo sapiens)	8 / 11	LEU A 542 VAL A 550 ALA A 565 MET A 623 GLY A 626 ASN A 677 ALA A 689 ASP A 690	7YS A9001 (-4.1A) 7YS A9001 (-4.2A) 7YS A9001 (-3.3A) 7YS A9001 (-4.7A) 7YS A9001 (-3.4A) None 7YS A9001 (-3.4A) None	0.67A	4u5jA-5u6bA: 30.9	4u5jA-5u6bA: 37.70
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4U5J_B_RXTB601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	5u6b	TYROSINE-PROTEIN KINASE RECEPTOR UFO (Homo sapiens)	6 / 9	LEU A 542 VAL A 550 ALA A 565 MET A 623 GLY A 626 ASP A 690	7YS A9001 (-4.1A) 7YS A9001 (-4.2A) 7YS A9001 (-3.3A) 7YS A9001 (-4.7A) 7YS A9001 (-3.4A) None	0.71A	4u5jB-5u6bA: 30.3	4u5jB-5u6bA: 37.70
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4WA9_A_AXIA9000_1 (TYROSINE-PROTEIN KINASE ABL1)	5u6b	TYROSINE-PROTEIN KINASE RECEPTOR UFO (Homo sapiens)	6 / 11	LEU A 542 ALA A 565 MET A 623 GLY A 626 ASN A 677 ALA A 689	7YS A9001 (-4.1A) 7YS A9001 (-3.3A) 7YS A9001 (-4.7A) 7YS A9001 (-3.4A) None 7YS A9001 (-3.4A)	0.71A	4wa9A-5u6bA: 28.0	4wa9A-5u6bA: 43.85
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4WA9_B_AXIB9000_1 (TYROSINE-PROTEIN KINASE ABL1)	5u6b	TYROSINE-PROTEIN KINASE RECEPTOR UFO (Homo sapiens)	7 / 12	VAL A 550 ALA A 565 LYS A 567 PHE A 622 MET A 623 GLY A 626 ALA A 689	7YS A9001 (-4.2A) 7YS A9001 (-3.3A) None 7YS A9001 (-4.3A) 7YS A9001 (-4.7A) 7YS A9001 (-3.4A) 7YS A9001 (-3.4A)	0.77A	4wa9B-5u6bA: 30.2	4wa9B-5u6bA: 43.85
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4WA9_B_AXIB9000_1 (TYROSINE-PROTEIN KINASE ABL1)	5u6b	TYROSINE-PROTEIN KINASE RECEPTOR UFO (Homo sapiens)	7 / 12	VAL A 550 ALA A 565 PHE A 622 MET A 623 GLY A 626 ASN A 677 ALA A 689	7YS A9001 (-4.2A) 7YS A9001 (-3.3A) 7YS A9001 (-4.3A) 7YS A9001 (-4.7A) 7YS A9001 (-3.4A) None 7YS A9001 (-3.4A)	0.78A	4wa9B-5u6bA: 30.2	4wa9B-5u6bA: 43.85
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5AAA_A_VGHA9000_1 (ALK TYROSINE KINASE RECEPTOR)	5u6b	TYROSINE-PROTEIN KINASE RECEPTOR UFO (Homo sapiens)	7 / 9	LEU A 542 VAL A 550 ALA A 565 LEU A 620 MET A 623 GLY A 626 ASP A 690	7YS A9001 (-4.1A) 7YS A9001 (-4.2A) 7YS A9001 (-3.3A) 7YS A9001 (-4.2A) 7YS A9001 (-4.7A) 7YS A9001 (-3.4A) None	0.51A	5aaaA-5u6bA: 30.6	5aaaA-5u6bA: 40.98
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5AAB_A_VGHA9000_1 (ALK TYROSINE KINASE RECEPTOR)	5u6b	TYROSINE-PROTEIN KINASE RECEPTOR UFO (Homo sapiens)	8 / 10	LEU A 542 VAL A 550 ALA A 565 LYS A 567 LEU A 620 MET A 623 GLY A 626 ASP A 690	7YS A9001 (-4.1A) 7YS A9001 (-4.2A) 7YS A9001 (-3.3A) None 7YS A9001 (-4.2A) 7YS A9001 (-4.7A) 7YS A9001 (-3.4A) None	0.61A	5aabA-5u6bA: 30.4	5aabA-5u6bA: 40.98
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5AAC_A_VGHA9000_1 (ALK TYROSINE KINASE RECEPTOR)	5u6b	TYROSINE-PROTEIN KINASE RECEPTOR UFO (Homo sapiens)	7 / 10	LEU A 542 VAL A 550 ALA A 565 LEU A 620 MET A 623 GLY A 626 ASP A 690	7YS A9001 (-4.1A) 7YS A9001 (-4.2A) 7YS A9001 (-3.3A) 7YS A9001 (-4.2A) 7YS A9001 (-4.7A) 7YS A9001 (-3.4A) None	0.57A	5aacA-5u6bA: 30.2	5aacA-5u6bA: 40.67
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5AAC_A_VGHA9000_1 (ALK TYROSINE KINASE RECEPTOR)	5u6b	TYROSINE-PROTEIN KINASE RECEPTOR UFO (Homo sapiens)	7 / 10	LEU A 542 VAL A 550 ALA A 565 LYS A 567 LEU A 620 MET A 623 GLY A 626	7YS A9001 (-4.1A) 7YS A9001 (-4.2A) 7YS A9001 (-3.3A) None 7YS A9001 (-4.2A) 7YS A9001 (-4.7A) 7YS A9001 (-3.4A)	0.66A	5aacA-5u6bA: 30.2	5aacA-5u6bA: 40.67
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5AJQ_A_DB8A800_1 (SERINE/THREONINE-PRO TEIN KINASE 10)	5u6b	TYROSINE-PROTEIN KINASE RECEPTOR UFO (Homo sapiens)	7 / 12	LEU A 542 ALA A 565 LYS A 567 PHE A 622 GLY A 626 ALA A 689 ASP A 690	7YS A9001 (-4.1A) 7YS A9001 (-3.3A) None 7YS A9001 (-4.3A) 7YS A9001 (-3.4A) 7YS A9001 (-3.4A) None	1.05A	5ajqA-5u6bA: 25.2	5ajqA-5u6bA: 28.88
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5AJQ_A_DB8A800_1 (SERINE/THREONINE-PRO TEIN KINASE 10)	5u6b	TYROSINE-PROTEIN KINASE RECEPTOR UFO (Homo sapiens)	7 / 12	LEU A 542 GLY A 543 ALA A 565 PHE A 622 GLY A 626 ALA A 689 ASP A 690	7YS A9001 (-4.1A) 7YS A9001 ( 4.2A) 7YS A9001 (-3.3A) 7YS A9001 (-4.3A) 7YS A9001 (-3.4A) 7YS A9001 (-3.4A) None	0.87A	5ajqA-5u6bA: 25.2	5ajqA-5u6bA: 28.88
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5MO4_A_NILA601_1 (TYROSINE-PROTEIN KINASE ABL1)	5u6b	TYROSINE-PROTEIN KINASE RECEPTOR UFO (Homo sapiens)	5 / 10	LEU A 542 VAL A 550 PHE A 622 MET A 623 GLY A 626	7YS A9001 (-4.1A) 7YS A9001 (-4.2A) 7YS A9001 (-4.3A) 7YS A9001 (-4.7A) 7YS A9001 (-3.4A)	0.58A	5mo4A-5u6bA: 25.8	5mo4A-5u6bA: 30.16
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6HD4_A_STIA604_1 (TYROSINE-PROTEIN KINASE ABL1)	5u6b	TYROSINE-PROTEIN KINASE RECEPTOR UFO (Homo sapiens)	4 / 5	VAL A 529 PHE A 622 MET A 623 GLY A 626	None 7YS A9001 (-4.3A) 7YS A9001 (-4.7A) 7YS A9001 (-3.4A)	1.34A	6hd4A-5u6bA: 29.5	6hd4A-5u6bA: 15.48
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6HD4_B_STIB602_1 (TYROSINE-PROTEIN KINASE ABL1)	5u6b	TYROSINE-PROTEIN KINASE RECEPTOR UFO (Homo sapiens)	4 / 6	LEU A 542 PHE A 622 MET A 623 GLY A 626	7YS A9001 (-4.1A) 7YS A9001 (-4.3A) 7YS A9001 (-4.7A) 7YS A9001 (-3.4A)	0.48A	6hd4B-5u6bA: 29.5	6hd4B-5u6bA: 15.48

[["DrReposER ID","Desc.","Hit PDB","Hit molecule","Hit organism","Res. no.","Interface","HETATM","RMSD","Z-score","Seq ID"],["1IEP_B_STIB202_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL","5u6b","TYROSINE-PROTEIN KINASE RECEPTOR UFO","Homo sapiens",6,"LEU A 542;VAL A 550;ALA A 565;PHE A 622;GLY A 626;ALA A 689","7YS A9001 (-4.1A);7YS A9001 (-4.2A);7YS A9001 (-3.3A);7YS A9001 (-4.3A);7YS A9001 (-3.4A);7YS A9001 (-3.4A)","0.75A","1iepB-5u6bA:29.7",null],["2G72_B_SAMB2002_1","PHENYLETHANOLAMINE N-METHYLTRANSFERASE","5u6b","TYROSINE-PROTEIN KINASE RECEPTOR UFO","Homo sapiens",4,"GLY A 692;TYR A 726;ASP A 690;ASP A 627","None;None;None;7YS A9001 (-3.5A)","0.90A","2g72B-5u6bA:undetectable","1iepB-5u6bA:43.40"],["2WGJ_A_VGHA2346_1","HEPATOCYTE GROWTH FACTOR RECEPTOR","5u6b","TYROSINE-PROTEIN KINASE RECEPTOR UFO","Homo sapiens",7,"GLY A 543;VAL A 550;ALA A 565;LEU A 620;MET A 623;GLY A 626;MET A 679","7YS A9001 ( 4.2A);7YS A9001 (-4.2A);7YS A9001 (-3.3A);7YS A9001 (-4.2A);7YS A9001 (-4.7A);7YS A9001 (-3.4A);7YS A9001 (-3.5A)","0.73A","2wgjA-5u6bA:32.6","2g72B-5u6bA:19.35"],["2WGJ_A_VGHA2346_1","HEPATOCYTE GROWTH FACTOR RECEPTOR","5u6b","TYROSINE-PROTEIN KINASE RECEPTOR UFO","Homo sapiens",8,"VAL A 550;ALA A 565;LEU A 620;MET A 623;GLY A 626;MET A 679;ALA A 689;ASP A 690","7YS A9001 (-4.2A);7YS A9001 (-3.3A);7YS A9001 (-4.2A);7YS A9001 (-4.7A);7YS A9001 (-3.4A);7YS A9001 (-3.5A);7YS A9001 (-3.4A);None","0.64A","2wgjA-5u6bA:32.6","2wgjA-5u6bA:41.61"],["2XP2_A_VGHA9000_1","TYROSINE-PROTEIN KINASE RECEPTOR","5u6b","TYROSINE-PROTEIN KINASE RECEPTOR UFO","Homo sapiens",7,"LEU A 542;VAL A 550;ALA A 565;LEU A 620;MET A 623;GLY A 626;ASP A 690","7YS A9001 (-4.1A);7YS A9001 (-4.2A);7YS A9001 (-3.3A);7YS A9001 (-4.2A);7YS A9001 (-4.7A);7YS A9001 (-3.4A);None","0.51A","2xp2A-5u6bA:30.5","2wgjA-5u6bA:41.61"],["3AOX_A_EMHA901_1","ALK TYROSINE KINASE RECEPTOR","5u6b","TYROSINE-PROTEIN KINASE RECEPTOR UFO","Homo sapiens",6,"LEU A 542;ALA A 565;LYS A 567;LEU A 620;MET A 623;GLY A 626","7YS A9001 (-4.1A);7YS A9001 (-3.3A);None;7YS A9001 (-4.2A);7YS A9001 (-4.7A);7YS A9001 (-3.4A)","0.68A","3aoxA-5u6bA:29.5","2xp2A-5u6bA:40.67"],["3CS9_A_NILA600_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","5u6b","TYROSINE-PROTEIN KINASE RECEPTOR UFO","Homo sapiens",5,"LEU A 542;VAL A 550;LYS A 567;PHE A 622;VAL A 688","7YS A9001 (-4.1A);7YS A9001 (-4.2A);None;7YS A9001 (-4.3A);None","0.89A","3cs9A-5u6bA:30.4","3aoxA-5u6bA:38.46"],["3CS9_A_NILA600_2","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","5u6b","TYROSINE-PROTEIN KINASE RECEPTOR UFO","Homo sapiens",5,"ALA A 565;GLY A 626;PHE A 668;HIS A 670;ALA A 689","7YS A9001 (-3.3A);7YS A9001 (-3.4A);None;None;7YS A9001 (-3.4A)","0.32A","3cs9A-5u6bA:30.4","3cs9A-5u6bA:43.27"],["3CS9_C_NILC600_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","5u6b","TYROSINE-PROTEIN KINASE RECEPTOR UFO","Homo sapiens",5,"ALA A 565;PHE A 622;PHE A 668;HIS A 670;ALA A 689","7YS A9001 (-3.3A);7YS A9001 (-4.3A);None;None;7YS A9001 (-3.4A)","0.53A","3cs9C-5u6bA:26.9","3cs9A-5u6bA:43.27"],["3CS9_D_NILD600_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","5u6b","TYROSINE-PROTEIN KINASE RECEPTOR UFO","Homo sapiens",6,"ALA A 565;PHE A 622;GLY A 626;PHE A 668;HIS A 670;ALA A 689","7YS A9001 (-3.3A);7YS A9001 (-4.3A);7YS A9001 (-3.4A);None;None;7YS A9001 (-3.4A)","0.49A","3cs9D-5u6bA:29.3","3cs9C-5u6bA:43.27"],["3MIY_A_B49A1_1","TYROSINE-PROTEIN KINASE ITK\/TSK","5u6b","TYROSINE-PROTEIN KINASE RECEPTOR UFO","Homo sapiens",6,"ALA A 565;LYS A 567;PHE A 622;MET A 623;GLY A 626;ASP A 690","7YS A9001 (-3.3A);None;7YS A9001 (-4.3A);7YS A9001 (-4.7A);7YS A9001 (-3.4A);None","0.81A","3miyA-5u6bA:32.2","3cs9D-5u6bA:43.27"],["3MIY_B_B49B2_1","TYROSINE-PROTEIN KINASE ITK\/TSK","5u6b","TYROSINE-PROTEIN KINASE RECEPTOR UFO","Homo sapiens",5,"ALA A 565;LYS A 567;PHE A 622;MET A 623;GLY A 626","7YS A9001 (-3.3A);None;7YS A9001 (-4.3A);7YS A9001 (-4.7A);7YS A9001 (-3.4A)","0.63A","3miyB-5u6bA:31.7","3miyA-5u6bA:36.93"],["3VAQ_A_ADNA401_2","PUTATIVE ADENOSINE KINASE","5u6b","TYROSINE-PROTEIN KINASE RECEPTOR UFO","Homo sapiens",4,"LEU A 620;ALA A 689;PHE A 691;ASN A 681","7YS A9001 (-4.2A);7YS A9001 (-3.4A);None;None","1.43A","3vaqA-5u6bA:undetectable","3miyB-5u6bA:36.93"],["3ZBF_A_VGHA3000_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS","5u6b","TYROSINE-PROTEIN KINASE RECEPTOR UFO","Homo sapiens",7,"LEU A 542;ALA A 565;LEU A 620;MET A 623;GLY A 626;ASP A 627;ASP A 690","7YS A9001 (-4.1A);7YS A9001 (-3.3A);7YS A9001 (-4.2A);7YS A9001 (-4.7A);7YS A9001 (-3.4A);7YS A9001 (-3.5A);None","0.63A","3zbfA-5u6bA:26.3","3vaqA-5u6bA:22.60"],["4ANQ_A_VGHA9000_1","ALK TYROSINE KINASE RECEPTOR","5u6b","TYROSINE-PROTEIN KINASE RECEPTOR UFO","Homo sapiens",8,"LEU A 542;VAL A 550;ALA A 565;LEU A 620;MET A 623;GLY A 626;ALA A 689;ASP A 690","7YS A9001 (-4.1A);7YS A9001 (-4.2A);7YS A9001 (-3.3A);7YS A9001 (-4.2A);7YS A9001 (-4.7A);7YS A9001 (-3.4A);7YS A9001 (-3.4A);None","0.60A","4anqA-5u6bA:30.3","3zbfA-5u6bA:38.07"],["4ANS_A_VGHA9000_1","ALK TYROSINE KINASE RECEPTOR","5u6b","TYROSINE-PROTEIN KINASE RECEPTOR UFO","Homo sapiens",7,"LEU A 542;VAL A 550;ALA A 565;MET A 623;GLY A 626;ALA A 689;ASP A 690","7YS A9001 (-4.1A);7YS A9001 (-4.2A);7YS A9001 (-3.3A);7YS A9001 (-4.7A);7YS A9001 (-3.4A);7YS A9001 (-3.4A);None","0.61A","4ansA-5u6bA:30.2","4anqA-5u6bA:40.30"],["4MXY_B_DB8B601_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","5u6b","TYROSINE-PROTEIN KINASE RECEPTOR UFO","Homo sapiens",7,"LEU A 542;VAL A 550;ALA A 565;LYS A 567;GLY A 626;ALA A 689;ASP A 690","7YS A9001 (-4.1A);7YS A9001 (-4.2A);7YS A9001 (-3.3A);None;7YS A9001 (-3.4A);7YS A9001 (-3.4A);None","0.65A","4mxyB-5u6bA:30.3","4ansA-5u6bA:40.48"],["4MXZ_B_DB8B601_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","5u6b","TYROSINE-PROTEIN KINASE RECEPTOR UFO","Homo sapiens",7,"LEU A 542;VAL A 550;ALA A 565;LYS A 567;GLY A 626;ALA A 689;ASP A 690","7YS A9001 (-4.1A);7YS A9001 (-4.2A);7YS A9001 (-3.3A);None;7YS A9001 (-3.4A);7YS A9001 (-3.4A);None","0.65A","4mxzB-5u6bA:30.3","4mxyB-5u6bA:37.38"],["4OTI_A_MI1A1001_1","SERINE\/THREONINE-PROTEIN KINASE N1","5u6b","TYROSINE-PROTEIN KINASE RECEPTOR UFO","Homo sapiens",7,"LEU A 542;GLY A 543;GLY A 545;GLY A 548;VAL A 550;ALA A 565;LYS A 567","7YS A9001 (-4.1A);7YS A9001 ( 4.2A);None;None;7YS A9001 (-4.2A);7YS A9001 (-3.3A);None","0.63A","4otiA-5u6bA:20.0","4mxzB-5u6bA:37.38"],["4TWP_A_AXIA601_1","TYROSINE-PROTEIN KINASE ABL1","5u6b","TYROSINE-PROTEIN KINASE RECEPTOR UFO","Homo sapiens",9,"LEU A 542;VAL A 550;ALA A 565;LYS A 567;PHE A 622;MET A 623;GLY A 626;ASN A 677;ASP A 690","7YS A9001 (-4.1A);7YS A9001 (-4.2A);7YS A9001 (-3.3A);None;7YS A9001 (-4.3A);7YS A9001 (-4.7A);7YS A9001 (-3.4A);None;None","0.75A","4twpA-5u6bA:30.4","4otiA-5u6bA:27.96"],["4TWP_A_AXIA601_1","TYROSINE-PROTEIN KINASE ABL1","5u6b","TYROSINE-PROTEIN KINASE RECEPTOR UFO","Homo sapiens",9,"VAL A 550;ALA A 565;LYS A 567;PHE A 622;MET A 623;GLY A 626;ASN A 677;ALA A 689;ASP A 690","7YS A9001 (-4.2A);7YS A9001 (-3.3A);None;7YS A9001 (-4.3A);7YS A9001 (-4.7A);7YS A9001 (-3.4A);None;7YS A9001 (-3.4A);None","0.72A","4twpA-5u6bA:30.4","4twpA-5u6bA:42.68"],["4TWP_B_AXIB601_1","TYROSINE-PROTEIN KINASE ABL1","5u6b","TYROSINE-PROTEIN KINASE RECEPTOR UFO","Homo sapiens",9,"LEU A 542;VAL A 550;ALA A 565;LYS A 567;PHE A 622;MET A 623;GLY A 626;ALA A 689;ASP A 690","7YS A9001 (-4.1A);7YS A9001 (-4.2A);7YS A9001 (-3.3A);None;7YS A9001 (-4.3A);7YS A9001 (-4.7A);7YS A9001 (-3.4A);7YS A9001 (-3.4A);None","0.79A","4twpB-5u6bA:30.2","4twpA-5u6bA:42.68"],["4TWP_B_AXIB601_1","TYROSINE-PROTEIN KINASE ABL1","5u6b","TYROSINE-PROTEIN KINASE RECEPTOR UFO","Homo sapiens",9,"LEU A 542;VAL A 550;ALA A 565;PHE A 622;MET A 623;GLY A 626;ASN A 677;ALA A 689;ASP A 690","7YS A9001 (-4.1A);7YS A9001 (-4.2A);7YS A9001 (-3.3A);7YS A9001 (-4.3A);7YS A9001 (-4.7A);7YS A9001 (-3.4A);None;7YS A9001 (-3.4A);None","0.76A","4twpB-5u6bA:30.2","4twpB-5u6bA:42.68"],["4U5J_A_RXTA601_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","5u6b","TYROSINE-PROTEIN KINASE RECEPTOR UFO","Homo sapiens",8,"LEU A 542;VAL A 550;ALA A 565;MET A 623;GLY A 626;ASN A 677;ALA A 689;ASP A 690","7YS A9001 (-4.1A);7YS A9001 (-4.2A);7YS A9001 (-3.3A);7YS A9001 (-4.7A);7YS A9001 (-3.4A);None;7YS A9001 (-3.4A);None","0.67A","4u5jA-5u6bA:30.9","4twpB-5u6bA:42.68"],["4U5J_B_RXTB601_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","5u6b","TYROSINE-PROTEIN KINASE RECEPTOR UFO","Homo sapiens",6,"LEU A 542;VAL A 550;ALA A 565;MET A 623;GLY A 626;ASP A 690","7YS A9001 (-4.1A);7YS A9001 (-4.2A);7YS A9001 (-3.3A);7YS A9001 (-4.7A);7YS A9001 (-3.4A);None","0.71A","4u5jB-5u6bA:30.3","4u5jA-5u6bA:37.70"],["4WA9_A_AXIA9000_1","TYROSINE-PROTEIN KINASE ABL1","5u6b","TYROSINE-PROTEIN KINASE RECEPTOR UFO","Homo sapiens",6,"LEU A 542;ALA A 565;MET A 623;GLY A 626;ASN A 677;ALA A 689","7YS A9001 (-4.1A);7YS A9001 (-3.3A);7YS A9001 (-4.7A);7YS A9001 (-3.4A);None;7YS A9001 (-3.4A)","0.71A","4wa9A-5u6bA:28.0","4u5jB-5u6bA:37.70"],["4WA9_B_AXIB9000_1","TYROSINE-PROTEIN KINASE ABL1","5u6b","TYROSINE-PROTEIN KINASE RECEPTOR UFO","Homo sapiens",7,"VAL A 550;ALA A 565;LYS A 567;PHE A 622;MET A 623;GLY A 626;ALA A 689","7YS A9001 (-4.2A);7YS A9001 (-3.3A);None;7YS A9001 (-4.3A);7YS A9001 (-4.7A);7YS A9001 (-3.4A);7YS A9001 (-3.4A)","0.77A","4wa9B-5u6bA:30.2","4wa9A-5u6bA:43.85"],["4WA9_B_AXIB9000_1","TYROSINE-PROTEIN KINASE ABL1","5u6b","TYROSINE-PROTEIN KINASE RECEPTOR UFO","Homo sapiens",7,"VAL A 550;ALA A 565;PHE A 622;MET A 623;GLY A 626;ASN A 677;ALA A 689","7YS A9001 (-4.2A);7YS A9001 (-3.3A);7YS A9001 (-4.3A);7YS A9001 (-4.7A);7YS A9001 (-3.4A);None;7YS A9001 (-3.4A)","0.78A","4wa9B-5u6bA:30.2","4wa9B-5u6bA:43.85"],["5AAA_A_VGHA9000_1","ALK TYROSINE KINASE RECEPTOR","5u6b","TYROSINE-PROTEIN KINASE RECEPTOR UFO","Homo sapiens",7,"LEU A 542;VAL A 550;ALA A 565;LEU A 620;MET A 623;GLY A 626;ASP A 690","7YS A9001 (-4.1A);7YS A9001 (-4.2A);7YS A9001 (-3.3A);7YS A9001 (-4.2A);7YS A9001 (-4.7A);7YS A9001 (-3.4A);None","0.51A","5aaaA-5u6bA:30.6","4wa9B-5u6bA:43.85"],["5AAB_A_VGHA9000_1","ALK TYROSINE KINASE RECEPTOR","5u6b","TYROSINE-PROTEIN KINASE RECEPTOR UFO","Homo sapiens",8,"LEU A 542;VAL A 550;ALA A 565;LYS A 567;LEU A 620;MET A 623;GLY A 626;ASP A 690","7YS A9001 (-4.1A);7YS A9001 (-4.2A);7YS A9001 (-3.3A);None;7YS A9001 (-4.2A);7YS A9001 (-4.7A);7YS A9001 (-3.4A);None","0.61A","5aabA-5u6bA:30.4","5aaaA-5u6bA:40.98"],["5AAC_A_VGHA9000_1","ALK TYROSINE KINASE RECEPTOR","5u6b","TYROSINE-PROTEIN KINASE RECEPTOR UFO","Homo sapiens",7,"LEU A 542;VAL A 550;ALA A 565;LEU A 620;MET A 623;GLY A 626;ASP A 690","7YS A9001 (-4.1A);7YS A9001 (-4.2A);7YS A9001 (-3.3A);7YS A9001 (-4.2A);7YS A9001 (-4.7A);7YS A9001 (-3.4A);None","0.57A","5aacA-5u6bA:30.2","5aabA-5u6bA:40.98"],["5AAC_A_VGHA9000_1","ALK TYROSINE KINASE RECEPTOR","5u6b","TYROSINE-PROTEIN KINASE RECEPTOR UFO","Homo sapiens",7,"LEU A 542;VAL A 550;ALA A 565;LYS A 567;LEU A 620;MET A 623;GLY A 626","7YS A9001 (-4.1A);7YS A9001 (-4.2A);7YS A9001 (-3.3A);None;7YS A9001 (-4.2A);7YS A9001 (-4.7A);7YS A9001 (-3.4A)","0.66A","5aacA-5u6bA:30.2","5aacA-5u6bA:40.67"],["5AJQ_A_DB8A800_1","SERINE\/THREONINE-PROTEIN KINASE 10","5u6b","TYROSINE-PROTEIN KINASE RECEPTOR UFO","Homo sapiens",7,"LEU A 542;ALA A 565;LYS A 567;PHE A 622;GLY A 626;ALA A 689;ASP A 690","7YS A9001 (-4.1A);7YS A9001 (-3.3A);None;7YS A9001 (-4.3A);7YS A9001 (-3.4A);7YS A9001 (-3.4A);None","1.05A","5ajqA-5u6bA:25.2","5aacA-5u6bA:40.67"],["5AJQ_A_DB8A800_1","SERINE\/THREONINE-PROTEIN KINASE 10","5u6b","TYROSINE-PROTEIN KINASE RECEPTOR UFO","Homo sapiens",7,"LEU A 542;GLY A 543;ALA A 565;PHE A 622;GLY A 626;ALA A 689;ASP A 690","7YS A9001 (-4.1A);7YS A9001 ( 4.2A);7YS A9001 (-3.3A);7YS A9001 (-4.3A);7YS A9001 (-3.4A);7YS A9001 (-3.4A);None","0.87A","5ajqA-5u6bA:25.2","5ajqA-5u6bA:28.88"],["5MO4_A_NILA601_1","TYROSINE-PROTEIN KINASE ABL1","5u6b","TYROSINE-PROTEIN KINASE RECEPTOR UFO","Homo sapiens",5,"LEU A 542;VAL A 550;PHE A 622;MET A 623;GLY A 626","7YS A9001 (-4.1A);7YS A9001 (-4.2A);7YS A9001 (-4.3A);7YS A9001 (-4.7A);7YS A9001 (-3.4A)","0.58A","5mo4A-5u6bA:25.8","5ajqA-5u6bA:28.88"],["6HD4_A_STIA604_1","TYROSINE-PROTEIN KINASE ABL1","5u6b","TYROSINE-PROTEIN KINASE RECEPTOR UFO","Homo sapiens",4,"VAL A 529;PHE A 622;MET A 623;GLY A 626","None;7YS A9001 (-4.3A);7YS A9001 (-4.7A);7YS A9001 (-3.4A)","1.34A","6hd4A-5u6bA:29.5","5mo4A-5u6bA:30.16"],["6HD4_B_STIB602_1","TYROSINE-PROTEIN KINASE ABL1","5u6b","TYROSINE-PROTEIN KINASE RECEPTOR UFO","Homo sapiens",4,"LEU A 542;PHE A 622;MET A 623;GLY A 626","7YS A9001 (-4.1A);7YS A9001 (-4.3A);7YS A9001 (-4.7A);7YS A9001 (-3.4A)","0.48A","6hd4B-5u6bA:29.5","6hd4A-5u6bA:15.48"]]